CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

207103Orig1s000

PROPRIETARY NAME REVIEW(S)
Date of This Review: September 5, 2014
Application Type and Number: NDA 207103
Product Name and Strength: Ibrance (Palbociclib) Capsules
75 mg, 100 mg and 125 mg
Product Type: Single Ingredient Product
Rx or OTC: Rx
Applicant/Sponsor Name: Pfizer
Submission Date: July 7, 2014
Panorama #: 2014-25815
DMEPA Primary Reviewer: Davis Mathew, PharmD
DMEPA Associate Director: Chi-Ming (Alice) Tu, PharmD
1 INTRODUCTION

The proposed proprietary name, Ibrance, was found acceptable in OSE Review # 2013-16612, dated April 24, 2014 under IND 069324. We note that product characteristics are the same for NDA 207103 currently under review as the IND. This memorandum is to communicate that DMEPA maintains the proposed proprietary name, Ibrance, is acceptable from both a promotional and safety perspective under the NDA 207103.

If you have further questions or need clarifications, please contact Frances Fahnbulleh, OSE project manager, at 301-796-0942.

1.1 COMMENTS TO THE APPLICANT

We have completed our review of the proposed proprietary name, Ibrance, and have concluded that this name is acceptable.

If any of the proposed product characteristics as stated in your July 7, 2014 submission are altered, the name must be resubmitted for review.
REFERENCES

1. Townsend O, Proprietary name review for Ibrance (IND 069324). Silver Spring (MD): Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Division of Medication Error Prevention and Analysis (US); 2014-04-24. OSE RCM No.: 2013-16612
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DAVIS MATHEW
09/05/2014

CHI-MING TU
09/05/2014

Reference ID: 3622927
Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology
Office of Medication Error Prevention and Risk Management

Proprietary Name Review

Date: April 24, 2014

Reviewers: Otto L. Townsend, PharmD
Division of Medication Error Prevention and Analysis

Team Leader: Chi-Ming (Alice) Tu, PharmD
Division of Medication Error Prevention and Analysis

Drug Name and Strength: Ibrance (Palbociclib) Capsules
75 mg, 100 mg, and 125 mg

Application Type/Number: IND 069324

Applicant/Sponsor: Pfizer, Inc.

OSE RCM #: 2013-16612

*** This document contains proprietary and confidential information that should not be released to the public.***

Reference ID: 3495331
# CONTENTS

1 INTRODUCTION ................................................................................................................... 1  
1.1 Regulatory History ........................................................................................................... 1  
1.2 Product Information.......................................................................................................... 1  
2 RESULTS ............................................................................................................................. 1  
2.1 Promotional Assessment ................................................................................................. 2  
2.2 Safety Assessment ......................................................................................................... 2  
3 CONCLUSIONS ..................................................................................................................... 3  
3.1 Comments to the Applicant ............................................................................................. 3  
4 REFERENCES ........................................................................................................................ 4  
APPENDICES ................................................................................................................................. 7
1 INTRODUCTION
This review evaluates the proposed proprietary name, Ibrance, from a safety and promotional perspective. The sources and methods used to evaluate the proposed name are outlined in the reference section and Appendix A respectively.

1.1 Regulatory History
The Applicant’s first proprietary name request for [REDACTED] was withdrawn after a teleconference in which DMEPA notified the Applicant of concerns with the currently marketed product, Trokendi (See DARRTS IND 069324, Internal Meeting Minutes, dated 10/08/2013). The Applicant submitted a request for proprietary name review for Ibrance on November 27, 2013.

1.2 Product Information
The following product information is provided in the November 27, 2013 proprietary name submission.

- Active Ingredient: palbociclib
- Indication of Use: In combination with letrozole for the treatment of postmenopausal women with ER (+)/HER2-negative locally advanced or metastatic breast cancer who have not received previous systemic treatment for their advanced disease
- Route of Administration: oral
- Dosage Form: capsules
- Strength: 75 mg, 100 mg, and 125 mg
- Dose and Frequency:
  - 125 mg once daily, for 21 continuous days (3 weeks), followed by 7 days (1 week) off treatment. Palbociclib is given in combination with letrozole 2.5 mg tablets taken orally, once daily, continuously.
  - Dose adjustments for toxicity: 100 mg/day or 75 mg/day for 21 continuous days (3 weeks), followed by 7 days (1 week) off treatment
- How Supplied: bottle containing 21 capsules.
- Storage: store at controlled room temperature, between 15°C - 30°C.

2 RESULTS
The following sections provide information obtained and considered in the overall evaluation of the proposed proprietary name.
2.1 PROMOTIONAL ASSESSMENT

The Office of Prescription Drug Promotion (OPDP) determined the proposed name is acceptable from a promotional perspective. DMEPA and the Division of Oncology Products I (DOP1) concurred with the findings of OPDP’s promotional assessment of the proposed name.

2.2 SAFETY ASSESSMENT

The following aspects were considered in the safety evaluation of the name.

2.2.1 United States Adopted Names (USAN) Search

The December 23, 2013 search of the United States Adopted Name (USAN) stems did not identify that a USAN stem is present in the proposed proprietary name.

2.2.2 Components of the Proposed Proprietary Name

The Applicant indicated in their submission that the proposed name, Ibrance, has no inherent meaning. This proprietary name is comprised of a single word that does not contain any components, such as a modifier, route of administration, dosage form. The intended pronunciation for Ibrance is “EYE-brans”.

2.2.4 FDA Name Simulation Studies

Fifty-nine practitioners participated in DMEPA’s prescription studies. The interpretations did not overlap with any currently marketed products or any products in the pipeline.

We did note that one respondent submitted the name, Ibrin. However, the product Ibrin (fibrinogen, I-125) is no longer marketed and there are no generic alternatives available. Nonetheless, we included Ibrin in Table 1 (Section 2.2.6) for further evaluation.

We also noted that another respondent submitted the name, Ibran, which is phonetically and orthographically similar to the name, Ibren, that was submitted during EPD. Since Ibren was already identified from EPD, we further evaluated Ibren in Appendix E. We have considered these variations in our look-alike and sound-alike searches and analysis (see Appendix B). Appendix C contains the results from the verbal and written prescription studies.

2.2.5 Comments from Other Review Disciplines at Initial Review

In response to the OSE, December 17, 2013 e-mail, the DOP1 did not forward any comments or concerns relating to the proposed proprietary name at the initial phase of the review.

2.2.6 Failure Mode and Effects Analysis of Similar Names

Appendix B lists possible orthographic and phonetic misinterpretations of the letters appearing in the proposed proprietary name, Ibrance. Table 1 lists the names with orthographic, phonetic, or spelling similarity to the proposed proprietary name, Ibrance identified by the primary reviewer, the Expert Panel Discussion (EPD), FDA Prescription Simulation studies, and other review disciplines.
Our analysis of the 16 names contained in Table 1 determined that none of the names will pose a risk for confusion as described in Appendices D through E.

2.2.7 Communication of DMEPA’s Analysis at Midpoint of Review

DMEPA communicated our findings to DOP1 via e-mail on April 16, 2014. At that time we also requested additional information or concerns that could inform our review. Per e-mail correspondence from DOP1 on April 24, 2014, they stated no additional concerns with the proposed proprietary name, Ibrance.

3 CONCLUSIONS

The proposed proprietary name is acceptable from both a promotional and safety perspective. If you have further questions or need clarifications, please contact Frances Fahnbulleh, OSE project manager, at 301-796-0942.

3.1 Comments to the Applicant

We have completed our review of the proposed proprietary name, Ibrance, and have concluded that this name is acceptable. Additionally, the proposed proprietary name must be submitted at the time of NDA submission. If any of the proposed product characteristics as stated in your November 27, 2013 submission are altered, the name must be resubmitted for review.
4 REFERENCES

1. Micromedex Integrated Index (http://csi.micromedex.com)
   Micromedex contains a variety of databases covering pharmacology, therapeutics, toxicology and diagnostics.

2. Phonetic and Orthographic Computer Analysis (POCA)
   POCA is a database which was created for the Division of Medication Error Prevention and Analysis, FDA. As part of the name similarity assessment, proposed names are evaluated via a phonetic/orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists which operates in a similar fashion.

3. Drug Facts and Comparisons, online version, St. Louis, MO (http://factsandcomparisons.com)
   Drug Facts and Comparisons is a compendium organized by therapeutic course; it contains monographs on prescription and OTC drugs, with charts comparing similar products. This database also lists the orphan drugs.

4. FDA Document Archiving, Reporting & Regulatory Tracking System [DARRTS]
   DARRTS is a government database used to organize Applicant and Sponsor submissions as well as to store and organize assignments, reviews, and communications from the review divisions.

5. Division of Medication Errors Prevention and Analysis proprietary name consultation requests
   This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis from the Access database/tracking system.

6. Drugs@FDA (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
   Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA approved brand name, generic drugs, therapeutic biological products, prescription and over-the-counter human drugs and discontinued drugs and “Chemical Type 6” approvals.

   USPTO provides information regarding patent and trademarks.

8. Clinical Pharmacology Online (www.clinicalpharmacology-ip.com)
   Clinical Pharmacology contains full monographs for the most common drugs in clinical use, plus mini monographs covering investigational, less common, combination, nutraceutical and nutritional products. It also provides a keyword search engine.
9. **Natural Medicines Comprehensive Databases** ([www.naturaldatabase.com](http://www.naturaldatabase.com))

Natural Medicines contains up-to-date clinical data on the natural medicines, herbal medicines, and dietary supplements used in the western world.

10. **Access Medicine** ([www.accessmedicine.com](http://www.accessmedicine.com))

Access Medicine® from McGraw-Hill contains full-text information from approximately 60 titles; it includes tables and references. Among the titles are: Harrison’s Principles of Internal Medicine, Basic & Clinical Pharmacology, and Goodman and Gilman’s The Pharmacologic Basis of Therapeutics.


USAN Stems List contains all the recognized USAN stems.


Red Book contains prices and product information for prescription, over-the-counter drugs, medical devices, and accessories.

13. **Lexi-Comp** ([www.lexi.com](http://www.lexi.com))

Lexi-Comp is a web-based searchable version of the Drug Information Handbook.

14. **Medical Abbreviations** ([www.medilexicon.com](http://www.medilexicon.com))

Medical Abbreviations dictionary contains commonly used medical abbreviations and their definitions.

15. **CVS/Pharmacy** ([www.CVS.com](http://www.CVS.com))

This database contains commonly used over the counter products not usually identified in other databases.

16. **Walgreens** ([www.walgreens.com](http://www.walgreens.com))

This database contains commonly used over the counter products not usually identified in other databases.

17. **Rx List** ([www.rxlist.com](http://www.rxlist.com))

RxList is an online medical resource dedicated to offering detailed and current pharmaceutical information on brand and generic drugs.

18. **Dogpile** ([www.dogpile.com](http://www.dogpile.com))

Dogpile is a Metasearch engine that searches multiple search engines including Google, Yahoo! and Bing, and returns the most relevant results to the search.

Natural Standard is a resource that aggregates and synthesizes data on complementary and alternative medicine.
APPENDICES

Appendix A

FDA’s Proprietary Name Risk Assessment considers the promotional and safety aspects of a proposed proprietary name. The promotional review of the proposed name is conducted by OPDP. OPDP evaluates proposed proprietary names to determine if they are overly fanciful, so as to misleadingly imply unique effectiveness or composition, as well as to assess whether they contribute to overstatement of product efficacy, minimization of risk, broadening of product indications, or making of unsubstantiated superiority claims. OPDP provides their opinion to DMEPA for consideration in the overall acceptability of the proposed proprietary name.

The safety assessment is conducted by DMEPA. DMEPA staff search a standard set of databases and information sources to identify names that are similar in pronunciation, spelling, and orthographically similar when scripted to the proposed proprietary name. Additionally, we consider inclusion of USAN stems or other characteristics that when incorporated into a proprietary name may cause or contribute to medication errors (i.e., dosing interval, dosage form/route of administration, medical or product name abbreviations, names that include or suggest the composition of the drug product, etc.). DMEPA defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. ¹

Following the preliminary screening of the proposed proprietary name, DMEPA gathers to discuss their professional opinions on the safety of the proposed proprietary name. This meeting is commonly referred to the Center for Drug Evaluation and Research (CDER) Expert Panel discussion. DMEPA also considers other aspects of the name that may be misleading from a safety perspective. DMEPA staff conducts a prescription simulation studies using FDA health care professionals. When provided, DMEPA considers external proprietary name studies conducted by or for the Applicant/Sponsor and incorporates the findings of these studies into the overall risk assessment.

The DMEPA primary reviewer assigned to evaluate the proposed proprietary name is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name. DMEPA bases the overall risk assessment on the findings of a Failure Mode and Effects Analysis (FMEA) of the proprietary name and misleading nature of the proposed proprietary name with a focus on the avoidance of medication errors.

DMEPA uses the clinical expertise of its staff to anticipate the conditions of the clinical setting where the product is likely to be used based on the characteristics of the proposed product. DMEPA considers the product characteristics associated with the proposed product throughout the risk assessment because the product characteristics of the proposed may provide a context for communication of the drug name and ultimately determine the use of the product in the usual clinical practice setting.

Typical product characteristics considered when identifying drug names that could potentially be confused with the proposed proprietary name include, but are not limited to; established name of the proposed product, proposed indication of use, dosage form, route of administration, strength, unit of measure, dosage units, recommended dose, typical quantity or volume, frequency of administration, product packaging, storage conditions, patient population, and prescriber population. DMEPA considers how these product characteristics may or may not be present in communicating a product name throughout the medication use system. Because drug name confusion can occur at any point in the medication use process, DMEPA considers the potential for confusion throughout the entire U.S. medication use process, including drug procurement, prescribing and ordering, dispensing, administration, and monitoring the impact of the medication.²

The DMEPA considers the spelling of the name, pronunciation of the name when spoken, and appearance of the name when scripted. DMEPA compares the proposed proprietary name with the proprietary and established name of existing and proposed drug products and names currently under review at the FDA. DMEPA compares the pronunciation of the proposed proprietary name with the pronunciation of other drug names because verbal communication of medication names is common in clinical settings. DMEPA examines the phonetic similarity using patterns of speech. If provided, DMEPA will consider the Sponsor’s intended pronunciation of the proprietary name. However, DMEPA also considers a variety of pronunciations that could occur in the English language because the Sponsor has little control over how the name will be spoken in clinical practice. The orthographic appearance of the proposed name is evaluated using a number of different handwriting samples. DMEPA applies expertise gained from root-cause analysis of postmarketing medication errors to identify sources of ambiguity within the name that could be introduced when scripting (e.g., “T” may look like “F,” lower case ‘a’ looks like a lower case ‘u,’ etc). Additionally, other orthographic attributes that determine the overall appearance of the drug name when scripted (see Table 1 below for details).

Table 1. Criteria Used to Identify Drug Names that Look- or Sound-Similar to a Proposed Proprietary Name.

<table>
<thead>
<tr>
<th>Type of Similarity</th>
<th>Considerations when Searching the Databases</th>
<th>Potential Causes of Drug Name Similarity</th>
<th>Attributes Examined to Identify Similar Drug Names</th>
<th>Potential Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Look-alike</td>
<td>Similar spelling</td>
<td>Identical prefix</td>
<td>Potential Causes of Drug Name Similarity</td>
<td>Names may appear similar in print or electronic media and lead to drug name confusion in printed or electronic communication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical infix</td>
<td></td>
<td>Names may look similar when scripted and lead to drug name confusion in written communication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical suffix</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Length of the name</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overlapping product characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Orthographic similarity</td>
<td>Similar spelling</td>
<td>Potential Causes of Drug Name Similarity</td>
<td>Names may look similar when scripted, and lead to drug name confusion in written communication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Length of the name/Similar shape</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Upstrokes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Down strokes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cross-strokes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dotted letters</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ambiguity introduced by scripting letters</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overlapping product characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sound-alike</td>
<td>Phonetic similarity</td>
<td>Identical prefix</td>
<td>Potential Causes of Drug Name Similarity</td>
<td>Names may sound similar when pronounced and lead to drug name confusion in verbal communication</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical infix</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Identical suffix</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Number of syllables</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stresses</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placement of vowel sounds</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placement of consonant sounds</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overlapping product characteristics</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Lastly, DMEPA considers the potential for the proposed proprietary name to inadvertently function as a source of error for reasons other than name confusion. Post-marketing experience has demonstrated that proprietary names (or components of the proprietary name) can be a source of error in a variety of ways. Consequently, DMEPA considers and evaluates these broader safety implications of the name throughout this assessment and the medication error staff provides additional comments related to the safety of the proposed proprietary name or product based on professional experience with medication errors.

1. **Database and Information Sources**

DMEPA searches the internet, several standard published drug product reference texts, and FDA databases to identify existing and proposed drug names that may sound-alike or look-alike to the proposed proprietary name. A standard description of the databases used in the searches is provided in the reference section of this review. To complement the process, the DMEPA uses a computerized method of identifying phonetic and orthographic similarity between medication names. The program, Phonetic and Orthographic Computer Analysis (POCA), uses complex algorithms to select a list of names from a database that have some similarity (phonetic, orthographic, or both) to the trademark being evaluated. Lastly, DMEPA reviews the USAN stem list to determine if any USAN stems are present within the proprietary name. The individual findings of multiple safety evaluators are pooled and presented to the CDER Expert Panel. DMEPA also evaluates if there are characteristics included in the composition that may render the name unacceptable from a safety perspective (abbreviation, dosing interval, etc.).

2. **Expert Panel Discussion**

DMEPA gathers CDER professional opinions on the safety of the proposed product and discussed the proposed proprietary name (Expert Panel Discussion). The Expert Panel is composed of Division of Medication Errors Prevention (DMEPA) staff and representatives from the Office of Prescription Drug Promotion (OPDP). We also consider input from other review disciplines (OND, ONDQA/OPB). The Expert Panel also discusses potential concerns regarding drug marketing and promotion related to the proposed names.

The primary Safety Evaluator presents the pooled results of the database and information searches to the Expert Panel for consideration. Based on the clinical and professional experiences of the Expert Panel members, the Panel may recommend additional names, additional searches by the primary Safety Evaluator to supplement the pooled results, or general advice to consider when reviewing the proposed proprietary name.

3. **FDA Prescription Simulation Studies**

Three separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of the proposed proprietary name with marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions or verbal pronunciation of the drug name. The studies employ healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The primary Safety Evaluator uses the results to identify orthographic or phonetic vulnerability of the proposed name to be misinterpreted by healthcare practitioners.
In order to evaluate the potential for misinterpretation of the proposed proprietary name in handwriting and verbal communication of the name, inpatient medication orders and/or outpatient prescriptions are written, each consisting of a combination of marketed and unapproved drug products, including the proposed name. These orders are optically scanned and one prescription is delivered to a random sample of participating health professionals via e-mail. In addition, a verbal prescription is recorded on voice mail. The voice mail messages are then sent to a random sample of the participating health professionals for their interpretations and review. After receiving either the written or verbal prescription orders, the participants record their interpretations of the orders which are recorded electronically.

4. Comments from Other Review Disciplines

DMEPA requests the Office of New Drugs (OND) and/or Office of Generic Drugs (OGD), ONDQA or OBP for their comments or concerns with the proposed proprietary name, ask for any clinical issues that may impact the DMEPA review during the initial phase of the name review. Additionally, when applicable, at the same time DMEPA requests concurrence/non-concurrence with OPDP’s decision on the name. The primary Safety Evaluator addresses any comments or concerns in the safety evaluator’s assessment.

The OND/OGD Regulatory Division is contacted a second time following our analysis of the proposed proprietary name. At this point, DMEPA conveys their decision to accept or reject the name. The OND or OGD Regulatory Division is requested to provide any further information that might inform DMEPA’s final decision on the proposed name.

Additionally, other review disciplines opinions such as ONDQA or OBP may be considered depending on the proposed proprietary name.

5. Safety Evaluator Risk Assessment of the Proposed Proprietary Name

The primary Safety Evaluator applies his/her individual expertise gained from evaluating medication errors reported to FDA, considers all aspects of the name that may be misleading or confusing, conducts a Failure Mode and Effects Analysis, and provides an overall decision on acceptability dependent on their risk assessment of name confusion. Failure Mode and Effects Analysis (FMEA) is a systematic tool for evaluating a process and identifying where and how it might fail. When applying FMEA to assess the risk of a proposed proprietary name, DMEPA seeks to evaluate the potential for a proposed proprietary name to be confused with another drug name because of name confusion and, thereby, cause errors to occur in the medication use system. FMEA capitalizes on the predictable and preventable nature of medication errors associated with drug name confusion. FMEA allows the Agency to identify the potential for medication errors due to orthographically or phonetically similar drug names prior to approval, where actions to overcome these issues are easier and more effective than remedies available in the post-approval phase.

In order to perform an FMEA of the proposed name, the primary Safety Evaluator must analyze the use of the product at all points in the medication use system. Because the proposed product is has not been marketed, the primary Safety Evaluator anticipates the use

---

of the product in the usual practice settings by considering the clinical and product characteristics listed in Section 1.2 of this review. The Safety Evaluator then analyzes the proposed proprietary name in the context of the usual practice setting and works to identify potential failure modes and the effects associated with the failure modes.

In the initial stage of the Risk Assessment, the Safety Evaluator compares the proposed proprietary name to all of the names gathered from the above searches, Expert Panel Discussion, and prescription studies, external studies, and identifies potential failure modes by asking:

“Is the proposed proprietary name convincingly similar to another drug name, which may cause practitioners to become confused at any point in the usual practice setting? And are there any components of the name that may function as a source of error beyond sound/look-alike?”

An affirmative answer indicates a failure mode and represents a potential for the proposed proprietary name to be confused with another proprietary or established drug name because of look- or sound-alike similarity or because of some other component of the name. If the answer to the question is no, the Safety Evaluator is not convinced that the names possess similarity that would cause confusion at any point in the medication use system, thus the name is eliminated from further review.

In the second stage of the Risk Assessment, the primary Safety Evaluator evaluates all potential failure modes to determine the likely effect of the drug name confusion, by asking:

“Could the confusion of the drug names conceivably result in medication errors in the usual practice setting?”

The answer to this question is a central component of the Safety Evaluator’s overall risk assessment of the proprietary name. If the Safety Evaluator determines through FMEA that the name similarity would not ultimately be a source of medication errors in the usual practice setting, the primary Safety Evaluator eliminates the name from further analysis. However, if the Safety Evaluator determines through FMEA that the name similarity could ultimately cause medication errors in the usual practice setting, the Safety Evaluator will then recommend the use of an alternate proprietary name.

Moreover, DMEPA will object to the use of proposed proprietary name when the primary Safety Evaluator identifies one or more of the following conditions in the Overall Risk Assessment:

a. OPDP finds the proposed proprietary name misleading from a promotional perspective, and the Review Division concurs with OPDP’s findings. The Federal Food, Drug, and Cosmetic Act provides that labeling or advertising can misbrand a product if misleading representations are made or suggested by statement, word, design, device, or any combination thereof, whether through a PROPRIETARY name or otherwise [21 U.S.C 321(n); See also 21 U.S.C. 352(a) & (n)].

b. DMEPA identifies that the proposed proprietary name is misleading because of similarity in spelling or pronunciation to another proprietary or established name of a different drug or ingredient [CFR 201.10.(C)(5)].
c. FMEA identifies the potential for confusion between the proposed proprietary name and other proprietary or established drug name(s), and demonstrates that medication errors are likely to result from the drug name confusion under the conditions of usual clinical practice.

d. The proposed proprietary name contains an USAN (United States Adopted Names) stem.

e. DMEPA identifies a potential source of medication error within the proposed proprietary name. For example, the proprietary name may be misleading or, inadvertently, introduce ambiguity and confusion that leads to errors. Such errors may not necessarily involve confusion between the proposed drug and another drug product but involve a naming characteristic that when incorporated into a proprietary name, may be confusing, misleading, cause or contribute to medication errors.

If DMEPA objects to a proposed proprietary name on the basis that drug name confusion could lead to medication errors, the primary Safety Evaluator uses the FMEA process to identify strategies to reduce the risk of medication errors. DMEPA generally recommends that the Sponsor select an alternative proprietary name and submit the alternate name to the Agency for review. However, in rare instances FMEA may identify plausible strategies that could reduce the risk of medication error of the currently proposed name. In that instance, DMEPA may be able to provide the Sponsor with recommendations that reduce or eliminate the potential for error and, thereby, would render the proposed name acceptable.

In the event that DMEPA objects to the use of the proposed proprietary name, based upon the potential for confusion with another proposed (but not yet approved) proprietary name, DMEPA will provide a contingency objection based on the date of approval. Whichever product, the Agency approves first has the right to use the proprietary name, while DMEPA will recommend that the second product to reach approval seek an alternative name.

The threshold set for objection to the proposed proprietary name may seem low to the Applicant/Sponsor. However, the safety concerns set forth in criteria a through e above are supported either by FDA regulation or by external healthcare authorities, including the Institute of Medicine (IOM), World Health Organization (WHO), the Joint Commission, and the Institute for Safe Medication Practices (ISMP). These organizations have examined medication errors resulting from look- or sound-alike drug names, confusing, or misleading names and called for regulatory authorities to address the issue prior to approval. Additionally, DMEPA contends that the threshold set for the Proprietary Name Risk Assessment is reasonable because proprietary drug name confusion is a predictable and preventable source of medication error that, in many instances, the Agency and/or Sponsor can identify and rectify prior to approval to avoid patient harm.

Furthermore, post-marketing experience has demonstrated that medication errors resulting from drug name confusion are notoriously difficult to rectify post-approval. Educational and other post-approval efforts are low-leverage strategies that have had limited effectiveness at alleviating medication errors involving drug name confusion. Sponsors have undertaken higher-leverage strategies, such as drug name changes, in the past but at great financial cost to the Sponsor and at the expense of the public welfare, not to mention the Agency’s credibility as the authority responsible for approving the error-prone proprietary name. Moreover, even after Sponsors’ have changed a product’s proprietary name in the post-approval phase, it is difficult to eradicate the original proprietary name from practitioners’
vocabulary, and as a result, the Agency has continued to receive reports of drug name confusion long after a name change in some instances. Therefore, DMEPA believes that post-approval efforts at reducing name confusion errors should be reserved for those cases in which the potential for name confusion could not be predicted prior to approval.
**Appendix B:** Letters and Letter Strings with Possible Orthographic or Phonetic Misinterpretation

<table>
<thead>
<tr>
<th>Letters in Name, proposed name</th>
<th>Scripted May Appear as</th>
<th>Spoken May Be Interpreted as</th>
</tr>
</thead>
<tbody>
<tr>
<td>Capital ‘T’</td>
<td>A, J, I, T</td>
<td>any vowel, eye</td>
</tr>
<tr>
<td>lowercase ‘i’</td>
<td>c, e, l</td>
<td>any vowel, eye</td>
</tr>
<tr>
<td>lowercase ‘b’</td>
<td>f, h, k, l</td>
<td>v</td>
</tr>
<tr>
<td>lowercase ‘r’</td>
<td>c, e, n, s, v</td>
<td>wr</td>
</tr>
<tr>
<td>lowercase ‘a’</td>
<td>ce, ci, cl, e, el, d, o, u</td>
<td>any vowel</td>
</tr>
<tr>
<td>lowercase ‘u’</td>
<td>h, m, r, s u, x,</td>
<td>kn, m</td>
</tr>
<tr>
<td>lowercase ‘c’</td>
<td>a, e, i, l</td>
<td>s, z</td>
</tr>
<tr>
<td>lowercase ‘e’</td>
<td>a, l, l o, u, p</td>
<td>any vowel</td>
</tr>
</tbody>
</table>

**Letter Strings**

| ce | u |
**Appendix C:** Prescription Simulation Samples and Results

**Figure 1. Ibrance Study (Conducted on December 27, 2013)**

<table>
<thead>
<tr>
<th>Handwritten Requisition Medication Order</th>
<th>Verbal Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medication Order:</strong></td>
<td>“Ibrance 125 mg daily as directed. Dispense quantity #21”</td>
</tr>
<tr>
<td>Ibrance 75 mg po daily for 21 days</td>
<td></td>
</tr>
</tbody>
</table>

| Outpatient Prescription:                |                     |
| Ibrance 125 mg daily as directed       |                     |
| #21                                     |                     |
### FDA Prescription Simulation Responses (Aggregate 1 Rx Studies Report)

200 People Received Study  
59 People Responded

**Study Name: Ibrance**

<table>
<thead>
<tr>
<th>INTERPRETATION</th>
<th>OUTPATIENT</th>
<th>VOICE</th>
<th>INPATIENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABRANCE</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>EYEBRANX</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>EYEBRINZ</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRACE</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRAN</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>IBRANCE</td>
<td>14</td>
<td>0</td>
<td>8</td>
<td>22</td>
</tr>
<tr>
<td>IBRAND</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRANDT</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRANTZ</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>IBRANZ</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>IBRARCE</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>IBRAX</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRENZ</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRENZE</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IBRIN</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>ILBRANCE</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>IVRANZ</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>SBRANCe</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>SHRANCE</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>UBRANCE</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>
**Appendix D:** Proprietary names not likely to be confused or not used in usual practice settings for the reasons described.

<table>
<thead>
<tr>
<th>No.</th>
<th>Proprietary Name</th>
<th>Active Ingredient</th>
<th>Similarity to Ibrance</th>
<th>Failure preventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Besivance</td>
<td>Besifloxacin</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>2.</td>
<td>Ellence</td>
<td>Epirubicin</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>3.</td>
<td>Elocon</td>
<td>Mometasone furoate</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>4.</td>
<td>Glucovance</td>
<td>Glyburide and Metformin HCl</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>5.</td>
<td>n/a</td>
<td>Ibandronate</td>
<td>Sound</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>6.</td>
<td>Iberet</td>
<td>Ferrous Sulfate, Vitamin B Complex, and Vitamin C</td>
<td>Look</td>
<td>Product no longer marketed and generics are not available.</td>
</tr>
<tr>
<td></td>
<td>Iberet-500</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Iberet-Folic-500</td>
<td>Ferrous Sulfate, Folic Acid, and Vitamin C</td>
<td>Look</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Ibrance</td>
<td>Palbociclib</td>
<td>Both</td>
<td>Name is the subject of this review.</td>
</tr>
<tr>
<td>8.</td>
<td>Ibrin</td>
<td>Fibrinogen, I-125</td>
<td>Sound</td>
<td>Product no longer marketed and generics are not available. FR effective date September 4, 1991</td>
</tr>
<tr>
<td>9.</td>
<td>Ilaria</td>
<td>Canakinumab</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>10.</td>
<td>Ilosone</td>
<td>Erythromycin Estolate</td>
<td>Look</td>
<td>Product no longer marketed and generics are not available. FR effective date: April 4, 2005.</td>
</tr>
<tr>
<td>11.</td>
<td>Librax</td>
<td>Chlordiazepoxide HCl and Clidinium Br</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
<tr>
<td>12.</td>
<td>Librium</td>
<td>Chlordiazepoxide HCl</td>
<td>Look</td>
<td>The pair have sufficient orthographic and/or phonetic differences</td>
</tr>
</tbody>
</table>
### Appendix E: Risk of medication errors due to product confusion minimized by dissimilarity of the names and/or use in clinical practice for the reasons described.

<table>
<thead>
<tr>
<th>No.</th>
<th>Proposed name:</th>
<th>Failure Mode: Incorrect Product Ordered/ Selected/Dispensed or Administered because of Name confusion Causes (could be multiple)</th>
<th>Prevention of Failure Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><em>Ibrance</em> (Palbociclib)</td>
<td>In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dosage Form:</strong> Oral Capsules</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strengths:</strong> 75 mg, 100 mg, and 125 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Usual Dose:</strong> 125 mg once daily by mouth, for 21 continuous days, followed by 7 days off treatment in combination with letrozole 2.5 mg tablets taken orally, once daily, continuously.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abraxane (Paclitaxel Protein-Bound)</td>
<td>Orthographic Similarities The names have similar prefixes, ‘ibra’ vs. ‘abra’, when scripted.</td>
<td>Orthographic Differences When scripted, the letter ‘x’ in the 5th position of Abraxane, differentiates the names.</td>
</tr>
<tr>
<td></td>
<td><strong>Dosage Form:</strong> Injection, Lyophilized Powder for suspension</td>
<td>Overlapping Product Characteristics Both products are available in 100 mg strengths. There are also dosage similarities between the two products. <em>Ibrance</em> is available as a 100 mg capsule and Abraxane is available as an injectable lyophilized powder for suspension containing 100 mg per vial. Further, the products have similar dosages. <em>Ibrance</em> can be prescribed as 100 mg or 125 mg while Abraxane may be prescribed as 100 mg/m² or 125 mg/m². Finally, both products are indicated in the treatment of breast cancer.</td>
<td>Product Characteristic Differences <em>Frequency of Administration</em> - <em>Ibrance</em> is an oral capsule that would be administered daily for 21 days vs. Abraxane, an injectable suspension that is administered as an infusion over 30 to 40 minutes on specified days of the treatment cycle (e.g., days 1, 8, 15, and 22).</td>
</tr>
<tr>
<td></td>
<td><strong>Strength</strong> 100 mg per Vial</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Usual Dose:</strong> Pancreatic Cancer: 125 mg/m² intravenous infusion over 30 to 40 minutes on days 1, 8, and 15 of 28-day cycle with gemcitabine Breast Cancer: 260 mg/m² intravenous infusion over 30 minutes every 3 weeks Non-Small Cell Lung Cancer: 100 mg/m² intravenous infusion over 30 minutes on days 1, 8, 15 of 21 day cycle.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reference ID: 3495331
<table>
<thead>
<tr>
<th>No.</th>
<th>Proposed name: <em>Ibrance</em> (Palbociclib)</th>
<th>Failure Mode: Incorrect Product Ordered/Selected/Dispensed or Administered because of Name confusion Causes (could be multiple)</th>
<th>Prevention of Failure Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Dosage Form:</strong> Oral Capsules</td>
<td>In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strengths:</strong> 75 mg, 100 mg, and 125 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Usual Dose:</strong> 125 mg once daily by mouth, for 21 continuous days, followed by 7 days off treatment in combination with letrozole 2.5 mg tablets taken orally, once daily, continuously.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*** This document contains proprietary and confidential information that should not be released to the public. ***

Reference ID: 3495331
| No. | Proposed name: **Ibrance**  
(Palbociclib) | Failure Mode: Incorrect Product Ordered/Selected/Dispensed or Administered because of Name confusion  
Causes (could be multiple) | Prevention of Failure Mode  
In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dosage Form: Oral Capsules</td>
<td></td>
</tr>
</tbody>
</table>
|  | Strengths:  
75 mg, 100 mg, and 125 mg | | |
|  | Usual Dose:  
125 mg once daily by mouth, for 21 continuous days, followed by 7 days off treatment in combination with letrozole  
2.5 mg tablets taken orally, once daily, continuously. | | |

|  | Phonetic Similarities  
The names have the same first syllable, ‘EYE’.  
Orthographic Similarities  
When scripted the name Ibren can appear as the prefix of Ibrance, ‘Ibran-’ because the letters ‘e’ and ‘a’ are similar in appearance.  
Overlapping Product Characteristics  
Both products are solid oral dosage forms administered by mouth. Further, an achievable dose of 600 mg could be attained with either product. However, six Ibrance 100 mg capsules would be an overdose. | | |
|  | Phonetic Differences  
The second syllables of the names differ, ‘brans’ vs. ‘bren’.  
Orthographic Differences  
The names are differentiated by the addition of the letter string, ‘ce’ which lengthens the name Ibrance.  
Product Characteristic Differences  
**Strengths** - 75 mg, 100 mg, and 125 mg vs. 600 mg | | |
|  | Ibren  
(Ibuprofen) | | |
|  | Dosage Form: Oral Tablet | | |
|  | Strength  
600 mg  
(Ibren was only available as 600 mg tablets. Product no longer available, but generics equivalents are available.) | | |
|  | Usual Dose:  
600 mg by mouth three to four times daily. | | |
| No. | Proposed name: **Ibrance**  
(Palbociclib) | Failure Mode: Incorrect Product Ordered/Selected/Dispensed or Administered because of Name confusion  
Causes (could be multiple) | Prevention of Failure Mode  
In the conditions outlined below, the following combination of factors, are expected to minimize the risk of confusion between these two names |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Dosage Form:</strong> Oral Capsules</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Strengths:</strong> 75 mg, 100 mg, and 125 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Usual Dose:</strong> 125 mg once daily by mouth, for 21 continuous days, followed by 7 days off treatment in combination with letrozole 2.5 mg tablets taken orally, once daily, continuously.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| 4.  | **Invanz**  
(Ertapenem)                             | **Phonetic Similarities**  
The names rhyme, ‘-ans’ vs. ‘-anz’. | **Phonetic Differences**  
The names have differing first syllables, ‘eye’ vs. ‘in’; and second syllables, ‘bran’ vs. ‘van’. |
|     | **Dosage Form:** Lyophilized Powder for Injection | **Overlapping Product Characteristics**  
The products are available in similar strengths. Ibrance is available as a 100 mg capsule and Invanz is available as a 1,000 mg (1 gm) lyophilized powder for injection vial. | **Product Characteristic Differences**  
*Route of Administration* – Oral vs. Intramuscular or Intravenous Injection |
|     | **Strength** 1 gm Vial                           |                                                                                 |                                                                                 |
|     | **Usual Dose:** Treatment: 1gm intravenously or intramuscularly once a day. Prophylaxis (colorectal surgery): 1 gm intravenously 1 hour prior to surgical incision. |                                                                                 |                                                                                 |
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

OTTO L TOWNSEND
04/24/2014

CHI-MING TU
04/24/2014